Stability Comparison Between Microglassification and Lyophilization Using a Monoclonal Antibody
Journal of Pharmaceutical Sciences · 2024
DOI: 10.1016/j.xphs.2023.10.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2024. Verfasst von Karthik Balakrishna Chandrababu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Lindy Biosciences, 627 Davis Dr. #400 Morrisville, North Carolina 27560, United States. Hauptthemen laut MEDLINE: Chemistry, Pharmaceutical, Biological Products. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: U.S. Department of Commerce, National Institute for Innovation in Manufacturing Biopharmaceuticals, National Institute of Standards and Technology.
Abstract (Originalsprache)
Producing solid-state formulations of biologics remains a daunting task despite the prevalent use of lyophilization and spray drying technologies in the biopharmaceutical industry. The challenges include protein stability (temperature stresses), high capital costs, particle design/controllability, shortened processing times and manufacturing considerations (scalability, yield improvements, aseptic operation, etc.). Thus, scientists/engineers are constantly working to improve existing methodologies and exploring novel dehydration/powder-forming technologies. Microglassification™ is a dehydration technology that uses solvent extraction to rapidly dehydrate protein formulations at ambient temperatures, eliminating the temperature stress experienced by biologics in traditional lyophilization and spray drying methods. The process results in microparticles that are spherical, dense, and chemically stable. In this study, we compared the molecular stability of a monoclonal antibody formulation processed by lyophilization to the same formulation processed using Microglassification™. Both powders were placed on stability for 3 months at 40 °C and 6 months at 25 °C. Both dehydration methods showed similar chemical stability, including percent monomer, charge variants, and antigen binding. These results show that Microglassification™ is viable for the production of stable solid-state monoclonal antibody formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lindy Biosciences, 627 Davis Dr. #400 Morrisville, North Carolina 27560, United States.
- Pharmaceutical Development, Genentech Inc., South San Francisco, CA 94080, United States.
- Pharmaceutical Development, Genentech Inc., South San Francisco, CA 94080, United States. Electronic address: saggu.miguel@gene.com.
- Lindy Biosciences, 627 Davis Dr. #400 Morrisville, North Carolina 27560, United States. Electronic address: dbitterfield@lindybio.com.
Förderung
- U.S. Department of Commerce
- National Institute for Innovation in Manufacturing Biopharmaceuticals
- National Institute of Standards and Technology
Zitieren
APA
Chandrababu, K. B., Kannan, A., Savage, J. R., Stadmiller, S., Ryle, A. E., Cheung, C., Kelley, R. F., Maa, Y. F., Saggu, M., & Bitterfield, D. L. (2024). Stability Comparison Between Microglassification and Lyophilization Using a Monoclonal Antibody. Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2023.10.021
Vancouver
Chandrababu KB, Kannan A, Savage JR, Stadmiller S, Ryle AE, Cheung C, et al. Stability Comparison Between Microglassification and Lyophilization Using a Monoclonal Antibody. Journal of Pharmaceutical Sciences. 2024. doi:10.1016/j.xphs.2023.10.021
BibTeX
@article{Chandrababu2024,
author = {Chandrababu, Karthik Balakrishna and Kannan, Aadithya and Savage, John R and Stadmiller, Samantha and Ryle, Adam E and Cheung, Chloe and Kelley, Robert F and Maa, Yuh-Fun and Saggu, Miguel and Bitterfield, Deborah L},
title = {Stability Comparison Between Microglassification and Lyophilization Using a Monoclonal Antibody},
journal = {Journal of Pharmaceutical Sciences},
year = {2024},
doi = {10.1016/j.xphs.2023.10.021}
}
EUVIMED